PhaseBio Secures $34 Million in Series D Financing

Author's Avatar
Sep 05, 2018
Article's Main Image

Proceeds will advance clinical development of PB2452, a potentially first-in-class reversal agent for patients on ticagrelor, and PB1046, a novel treatment for PAH